AAL

Biotech Stock Hits 2-Year Low as Vaccine Sales Decline

BioNTech reported lower-than-expected second-quarter revenue

Deputy Editor
Aug 7, 2023 at 11:05 AM
facebook X logo linkedin


BioNTech SE (NASDAQ:BNTX) is sinking to two-year lows today, after plunging Covid vaccine sales weighed on the company's second-quarter results. The biotech name reported narrower-than-expected losses of 79 cents per share alongside a revenue miss, with the company reducing its drug development as well. 

At last glance, BNTX was down 9.4% at $96.45, and on the short sell restricted (SSR) list. Before today, the $110 level was keeping a cap on gains, as well as overhead pressure from the stock's 80-day moving average. Year-to-date, the equity is down 35.5%. 

BioNTech stock's typically quiet options pits have seen 4.1 times the average daily options volume already, with 2,539 calls and 3,311 puts exchanged so far. The August 95 puts is the most active contract, with new positions being opened there. 

Analysts have yet to chime in on the results. Of the 17 in coverage, 11 carry a "buy" or better rating on BNTX, with six a tepid "hold." The 12-month consensus price target of $164.56 is a 68.8% premium to current levels. 

 

Same-Day Trading Power: +227% YTD and Counting  — Get in for $10!

We're celebrating 44 years of helping traders win, and you can now tap into one of our most explosive services — Dynamite Day Trading Signals — for just $10.

This service was built for one thing: capturing intraday gains with precision. 

Access two highly-vetted options trades each week -  Complete with defined entries, exits, and a clear plan for same-day profits.

👉 Click Here to Learn More and Position Yourself to Take Action When the Next Alert Hits.